Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 25.4%

AlloVir, Inc. (NASDAQ:ALVR) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,260,000 shares, a decline of 25.4% from the December 15th total of 1,690,000 shares. Based on an average trading volume of 370,200 shares, the short-interest ratio is currently 3.4 days.

Institutional Investors Weigh In On AlloVir

A hedge fund recently bought a new stake in AlloVir stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in AlloVir, Inc. (NASDAQ:ALVR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 76,278 shares of the company’s stock, valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. owned 0.07% of AlloVir at the end of the most recent reporting period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

AlloVir Price Performance

Shares of AlloVir stock opened at $9.00 on Friday. AlloVir has a 1 year low of $7.96 and a 1 year high of $24.15. The company has a market capitalization of $1.04 billion, a P/E ratio of -10.23 and a beta of 0.65. The business has a 50-day moving average of $0.51 and a two-hundred day moving average of $0.69.

AlloVir (NASDAQ:ALVR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.